MedMira (MedMira) Institutional Ownership : 0.01% (As of Jun. 15, 2024)

View and export this data going back to . Start your Free Trial

What is MedMira Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MedMira's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MedMira's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MedMira's Float Percentage Of Total Shares Outstanding is 0.00%.

MedMira Institutional Ownership Historical Data

The historical data trend for MedMira's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Institutional Ownership Chart

MedMira Historical Data

The historical data trend for MedMira can be seen below:

	2006-04-30	2006-05-31	2006-06-30	2006-07-31	2006-08-31	2006-09-30	2006-10-31	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	0.06	0.06	0.06	0.06	0.06	0.06	0.04	0.01	0.01	0.01

MedMira Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

MedMira (MedMira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

47M:Germany MIR:Canada

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.